Boston Scientific Corp (BSX)vsCo-Diagnostics, Inc. Common Stock (CODX)
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
CODX
Co-Diagnostics, Inc. Common Stock
$5.63
-2.26%
HEALTHCARE · Cap: $20.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 2870251% more annual revenue ($20.61B vs $718,170). BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CODX
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for CODX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Reasonable price relative to book value
Revenue surging 190.3% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 30.8% YoY
Areas to Watch
No major concerns identified
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -302.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CODX
The strongest argument for CODX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 190.3% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : CODX
The primary concerns for CODX are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while CODX is a hypergrowth play — different risk/reward profiles.
CODX carries more volatility with a beta of 1.26 — expect wider price swings.
CODX is growing revenue faster at 190.3% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 38/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Co-Diagnostics, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?